Therapeutic Applications and Challenges of a Widely Used Antifolate Drug
DOI:
https://doi.org/10.12775/QS.2024.16.52214Keywords
methotrexate, overdose, rheumatoid arthritis, toxicity, patient challengesAbstract
Introduction and purpose: Methotrexate (MTX) is an antifolate metabolite that interferes with the synthesis and repair of DNA and with cell replication. It has anti-inflammatory and immunomodulatory properties and was first used in 1951 for the treatment of RA and psoriasis. Methotrexate (4-amino-10-methylfolic acid, MTX) is a popular disease-modifying drug for the treatment of rheumatoid arthritis, psoriasis and leukaemia. MTX is an antagonist of folic acid, primarily through inhibition of the proliferative effect. MTX and its metabolites are associated with many serious adverse effects, including gastrointestinal and hepatic toxicity, myelosuppression, stomatitis, etc. Taking methotrexate may contribute to a reduction in the quality of life for patients. Additionally, long-term use of methotrexate requires regular monitoring, which can be burdensome and stressful for patients. In this context, different approaches have been used to improve the therapeutic properties of MTX and to reduce its adverse effects. The long history of the drug has made it possible to assess its efficacy and to collect data on adverse events, including potentially life-threatening adverse events. This article aims to provide a literature-based overview of current knowledge about methotrexate in clinical practice.
Materials and Methods: Review and summary of research studies available in open-source format on Google Scholar, PubMed.
Conclusion: The result is a picture of methotrexate as a drug that is used for many conditions, but is associated with many side effects that can be a significant problem for patients and healthcare professionals.
References
Zhao, Z., Hua, Z., Luo, X., Li, Y., Yu, L., Li, M., Lu, C., Zhao, T., & Liu, Y. (2022). Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomedecine & Pharmacotherapie [Biomedicine & Pharmacotherapy], 150(113074), 113074. https://doi.org/10.1016/j.biopha.2022.113074
Bello, A., Perkins, E., Jay, R., & Efthimiou, P. (2017). Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology: Research and Reviews, 9, 67–79. https://doi.org/10.2147/oarrr.s131668
Song, Z., Hu, Y., Liu, S., Wang, G., Zhai, S., Zhang, X., Li, Y., Du, G., Shi, Y., Chen, Y., Dong, M., Guo, R., Guo, W., Huang, H., Huang, X., Jing, H., Ke, X., Li, G., Miao, L., … Zhao, R. (2022). Medication therapy of high‐dose methotrexate: An evidence‐based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. British Journal of Clinical Pharmacology, 88(5), 2456–2472. https://doi.org/10.1111/bcp.15134
Hamed, K. M., Dighriri, I. M., Baomar, A. F., Alharthy, B. T., Alenazi, F. E., Alali, G. H., Alenazy, R. H., Alhumaidi, N. T., Alhulayfi, D. H., Alotaibi, Y. B., Alhumaidan, S. S., Alhaddad, Z. A., Humadi, A. A., Alzahrani, S. A., & Alobaid, R. H. (2022). Overview of methotrexate toxicity: A comprehensive literature review. Cureus, 14(9). https://doi.org/10.7759/cureus.29518
Charakterystyka produktu leczniczego Methofill 2,5mg tabletki substancja czynna metotreksat
https://www.mp.pl/pacjent/leki/subst.html?id=556
Charakterystyka produktu leczniczego Ebetrexat 10mg/ml roztwór do wstrzykiwań
STL Volume 24 Number. (2019, December 1). Brief update on dermatologic uses of methotrexate. Skin Therapy Letter. https://www.skintherapyletter.com/psoriasis/methotrexate-dermatologic-uses/
Patel, V., Wang, Y., MacDonald, J. K., McDonald, J. W. D., & Chande, N. (2014). Methotrexate for maintenance of remission in Crohn’s disease. The Cochrane Library, 2014(8). https://doi.org/10.1002/14651858.cd006884.pub3
Toksvang, L. N., Lee, S. H. R., Yang, J. J., & Schmiegelow, K. (2022). Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. Leukemia, 36(7), 1749–1758. https://doi.org/10.1038/s41375-022-01591-4
Nokhatha, Shamma & Harrington, Robert & Conway, Richard. (2020). Methotrexate and The Lung in Rheumatoid Arthritis. EMJ Rheumatology. 80-90. https://doi.org/10.33590/emjrheumatol/20-00074
Ross, K. C., Chin, K. F., Kim, D., Marion, C. D., Yen, T. J., & Bhattacharjee, V. (2018). Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget, 9(17), 13324–13336. https://doi.org/10.18632/oncotarget.24341
Salehi M, Miller R, Khaing M. Methotrexate-induced Hypersensitivity Pneumonitis appearing after 30 years of use: a case report. J Med Case Rep. 2017;11(1):174. doi: 10.1186/s13256-017-1333-0
Yamakawa, H., Yoshida, M., Takagi, M., & Kuwano, K. (2014). Late-onset methotrexate-induced pneumonitis with neutrophilia in bronchoalveolar lavage fluid. BMJ Case Reports, 2014(sep29 1), bcr2014206123–bcr2014206123. https://doi.org/10.1136/bcr-2014-206123
Dong, H., Cedars-Sinai Medical Center, Los Angeles, CA, USA, Julien, P. J., Demoruelle, M. K., Deane, K. D., Weisman, M. H., Cedars-Sinai Medical Center, Los Angeles, CA, USA, University of Colorado - Denver. Aurora, CO, USA, University of Colorado - Denver. Aurora, CO, USA, & Cedars-Sinai Medical Center, Los Angeles, CA, USA. (2019). Interstitial lung abnormalities in patients with early rheumatoid arthritis: A pilot study evaluating prevalence and progression. European Journal of Rheumatology, 6(4), 193–198. https://doi.org/10.5152/eurjrheum.2019.19044
Nagaraj S, Joshi P, Joshi VR. Methotrexate induced pneumonitis. Indian J Rheumatol2022;7:83. DOI: 10.1016/J. INJR.2012.04.001.
Jacobs, S. A., Stoller, R. G., Chabner, B. A., & Johns, D. G. (1976). 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. The Journal of Clinical Investigation, 57(2), 534–538. https://doi.org/10.1172/jci108308
Snyder, R., Urazov, A., Deh, M., Kulkarni, A., Chen, P.-J., Raju, G., Tanni, M., & Xu, Y. (2023). High dose methotrexate (MTX) treatment: Value of post treatment MTX level monitoring and risk factors for acute kidney injury. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 41(16_suppl), e19539–e19539. https://doi.org/10.1200/jco.2023.41.16_suppl.e19539
Bhargava, M., Kopp, C. R., Naidu, S., Dhibar, D. P., Saroch, A., Khadwal, A., Narang, T., Jain, S., Khullar, A., Leishangthem, B., Sharma, A., Kumar, S., Sharma, S., Jain, S., & Dhir, V. (2023). Comparison of two doses of leucovorin in severe low-dose methotrexate toxicity – a randomized controlled trial. Arthritis Research & Therapy, 25(1). https://doi.org/10.1186/s13075-023-03054-2
Cheung, K. K. T., Chow, K. M., Szeto, C. C., Leung Tai, M. H., Kwan, B. C. H., & Li, P. K. T. (2009). Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 15(4), 177–180. https://doi.org/10.1097/rhu.0b013e3181a61f2d
Gutierrez-Ureńa, S., Molina, J. F., García, C. O., Cuéllar, M. L., & Espinoza, L. R. (1996). Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis and Rheumatism, 39(2), 272–276. https://doi.org/10.1002/art.1780390214
Mameli, A., Barcellona, D., & Marongiu, F. (2017). Fatal cytopenia induced by low-dose methotrexate in elderly with rheumatoid arthritis. Identification of risk factors. American Journal of Therapeutics, 24(1), e106–e107. https://doi.org/10.1097/mjt.0000000000000486
Sherbini, A. A., Gwinnutt, J. M., Hyrich, K. L., Adebajo, A., Ahmed, K., Al-Ansari, A., Amarasena, R., Bukhari, M., Callan, M., Chelliah, E. G., Chinoy, H., Cooper, A., Dasgupta, B., Davis, M., Galloway, J., Gough, A., Green, M., Gullick, N., Hamilton, J., … RAMS Co-Investigators. (2022). Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology (Oxford, England), 61(10), 3930–3938. https://doi.org/10.1093/rheumatology/keab917
Basile, M. S., Ciurleo, R., Bramanti, A., Petralia, M. C., Fagone, P., Nicoletti, F., & Cavalli, E. (2021). Cognitive decline in rheumatoid arthritis: Insight into the molecular pathogenetic mechanisms. International Journal of Molecular Sciences, 22(3), 1185. https://doi.org/10.3390/ijms22031185
Bergström, B., Carlsten, H., & Ekwall, A.-K. H. (2018). Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1β on rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Research & Therapy, 20(1). https://doi.org/10.1186/s13075-018-1554-7
Dahi, M. G. C., Gregory, M. M., & Scheuer, P. J. (1971). Liver Damage due to Methotrexate in Patients with Psoriasis. Br Med J, 1(5750), 625–630. https://doi.org/10.1136/bmj.1.5750.625
Clary DD, Reid AT, Kiani R, Fanciullo J. Methotrexate Hepatotoxicity Monitoring Guidelines in Psoriasis and Rheumatoid Arthritis: Is There a Consensus? S D Med. 2021 Aug;74(8):363-366. PMID: 34461001.
Curtis, J. R., Beukelman, T., Onofrei, A., Cassell, S., Greenberg, J. D., Kavanaugh, A., Reed, G., Strand, V., & Kremer, J. M. (2010). Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Annals of the Rheumatic Diseases, 69(01), 43–47. https://doi.org/10.1136/ard.2008.101378
Walker, A. M., Funch, D., Dreyer, N. A., Tolman, K. G., Kremer, J. M., Alarcón, G. S., Lee, R. G., & Weinblatt, M. E. (1993). Determinants of serious liver disease among patients receiving low‐dose methotrexate for rheumatoid arthritis. Arthritis and Rheumatism, 36(3), 329–335. https://doi.org/10.1002/art.1780360307
Daniel S. García, Etel I. Saturansky, Daniel Poncino, Yamila Martínez-Artola, Silvia Rosenberg, Gloria Abritta, Carlos Ascimani-Peńa, Amerys Cravero, “Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?”, Annals of Hepatology, Volume 18, Issue 5, 2019, Pages 765-769, ISSN 1665-2681, https://doi.org/10.1016/j.aohep.2019.01.011.
Zhou, B., Xia, X., Wang, P., Chen, S., Yu, C., Huang, R., Zhang, R., Wang, Y., Lu, L., Yuan, F., Tian, Y., Fan, Y., Zhang, X., Shu, Y., Zhang, S., Bai, D., Wu, L., Xu, H., & Yang, L. (2018). Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut Microbiota. EBioMedicine, 33, 122–133. https://doi.org/10.1016/j.ebiom.2018.06.029
Saleh, J. Z., Lee, L. H., Schieke, S. M., Hosking, P. R., & Hwang, S. T. (2016). Methotrexate-induced CD30+ T-cell lymphoproliferative disorder of the oral cavity. JAAD Case Reports, 2(4), 354–356. https://doi.org/10.1016/j.jdcr.2016.02.002
Boukhettala, N., Leblond, J., Claeyssens, S., Faure, M., Le Pessot, F., Bôle-Feysot, C., Hassan, A., Mettraux, C., Vuichoud, J., Lavoinne, A., Breuillé, D., Déchelotte, P., & Coëffier, M. (2009). Methotrexate induces intestinal mucositis and alters gut protein metabolism independently of reduced food intake. American Journal of Physiology. Endocrinology and Metabolism, 296(1), E182–E190. https://doi.org/10.1152/ajpendo.90459.2008
Morsy, M., El-Sheikh, A., & Hamouda, A. (2016). Protective mechanisms of thymoquinone on methotrexate-induced intestinal toxicity in rats. Pharmacognosy Magazine, 12(45), 76. https://doi.org/10.4103/0973-1296.176106
Gautam, R., Singh, M., Gautam, S., Rawat, J. K., Saraf, S. A., & Kaithwas, G. (2016). Rutin attenuates intestinal toxicity induced by Methotrexate linked with anti-oxidative and anti-inflammatory effects. BMC Complementary and Alternative Medicine, 16(1). https://doi.org/10.1186/s12906-016-1069-1
Katsoulas, N., Chrysomali, E., Piperi, E., Levidou, G., & Sklavounou-Andrikopoulou, A. (2016). Atypical methotrexate ulcerative stomatitis with features of lymphoproliferative like disorder: Report of a rare ciprofloxacin-induced case and review of the literature. Journal of Clinical and Experimental Dentistry, 8(5), 0–0. https://doi.org/10.4317/jced.52909
West, J., Ogston, S., & Foerster, J. (2016). Safety and efficacy of methotrexate in psoriasis: A meta-analysis of published trials. PloS One, 11(5), e0153740. https://doi.org/10.1371/journal.pone.0153740
Hamed, K. M., Dighriri, I. M., Baomar, A. F., Alharthy, B. T., Alenazi, F. E., Alali, G. H., Alenazy, R. H., Alhumaidi, N. T., Alhulayfi, D. H., Alotaibi, Y. B., Alhumaidan, S. S., Alhaddad, Z. A., Humadi, A. A., Alzahrani, S. A., & Alobaid, R. H. (2022). Overview of methotrexate toxicity: A comprehensive literature review. Cureus, 14(9). https://doi.org/10.7759/cureus.29518
Motegi, S., & Ishikawa, O. (2014). Methotrexate-induced accelerated nodulosis in a patient with rheumatoid arthritis and Scleroderma. Acta Dermato-Venereologica, 94(3), 357–358. https://doi.org/10.2340/00015555-1720
Brady, P. C. (2017). New evidence to guide ectopic pregnancy diagnosis and management. Obstetrical & Gynecological Survey, 72(10), 618–625. https://doi.org/10.1097/ogx.0000000000000492
Dolinko, A. V., Vrees, R. A., & Frishman, G. N. (2018). Non-tubal ectopic pregnancies: Overview and treatment via local injection. Journal of Minimally Invasive Gynecology, 25(2), 287–296. https://doi.org/10.1016/j.jmig.2017.07.008
Tsakiridis, I., Giouleka, S., Mamopoulos, A., Athanasiadis, A., & Dagklis, T. (2020). Diagnosis and management of ectopic pregnancy: A comparative review of major national guidelines. Obstetrical & Gynecological Survey, 75(10), 611–623. https://doi.org/10.1097/ogx.0000000000000832
Po, L., Thomas, J., Mills, K., Zakhari, A., Tulandi, T., Shuman, M., & Page, A. (2021). Guideline no. 414: Management of pregnancy of unknown location and tubal and nontubal ectopic pregnancies. Journal d’obstetrique et Gynecologie Du Canada [Journal of Obstetrics and Gynaecology Canada], 43(5), 614-630.e1. https://doi.org/10.1016/j.jogc.2021.01.002
Zhao, M., Wang, X., He, M., Qin, X., Tang, G., Huo, Y., Li, J., Fu, J., Huang, X., Cheng, X., Wang, B., Hou, F. F., Sun, N., & Cai, Y. (2017). Homocysteine and stroke risk: Modifying effect of methylenetetrahydrofolate reductase C677T polymorphism and folic acid intervention. Stroke; a Journal of Cerebral Circulation, 48(5), 1183–1190. https://doi.org/10.1161/strokeaha.116.015324
Inaba, H., Khan, R. B., Laningham, F. H., Crews, K. R., Pui, C.-H., & Daw, N. C. (2008). Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Annals of Oncology, 19(1), 178–184. https://doi.org/10.1093/annonc/mdm466
Cruz-Carreras, M. T., Chaftari, P., Shamsnia, A., Guha-Thakurta, N., & Gonzalez, C. (2017). Methotrexate‐induced leukoencephalopathy presenting as stroke in the emergency department. Clinical Case Reports, 5(10), 1644–1648. https://doi.org/10.1002/ccr3.1110
Bhojwani, D., Bansal, R., & Wayne, A. S. (2021). Managing therapy-associated neurotoxicity in children with ALL. Hematology, 2021(1), 376–383. https://doi.org/10.1182/hematology.2021000269
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Rafał Makuch, Alicja Chrościcka , Kamil Gała, Andrzej Czajka, Paweł Lenard, Adam Kucharski, Sara Michalska, Konrad Pilarski, Martyna Dewicka, Alicja Maria Wawrzyniak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 174
Number of citations: 0
